Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Crispr Therapeutics AG (1CG) Drug Pipeline

22 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Ctx460Alpha-1 Antitrypsin Deficiency (Aatd)phase1AndPhase2RecruitingA Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)Sep 21, 2026―
Ctx112Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Stiff-Person Syndrome, Progressive Multiple Sclerosis (Pms), Neuromyelitis Optica, Autoimmune Encephalitisphase1AndPhase2Not Yet RecruitingA Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune DiseaseAug 12, 2026
Ctx340Hypertensionphase1AndPhase2RecruitingA Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With HypertensionAug 06, 2026
Ctx112Immune Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia (Waiha), Warm Autoimmune Hemolytic Anemia, Itp - Immune Thrombocytopeniaphase1AndPhase2RecruitingSafety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune DiseaseApr 08, 2026
Ctx310Hypertriglyceridemia, Homozygous Familial Hypercholesterolemia (Hofh), Hypercholesterolaemia, Dyslipidemias, Metabolic Disease, Severe Hypertriglyceridemia (Shtg), Cardiovascular, Lipid Disorder, Heterozygous Familial Hypercholesterolemia (Hefh), Mixed HyperlipemiaPhase IRecruitingA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory DyslipidemiasMar 18, 2026
Ctx112Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Myositis, Sle (Systemic Lupus), Inflammatory Myopathy, Idiopathic, Diffuse Cutaneous Systemic SclerosisPhase IRecruitingA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseaseMar 25, 2025―
Ctx131Acute Myeloid Leukemia, T Cell Lymphoma, B Cell LymphomaPhase ICompletedA Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic MalignanciesJun 21, 2024
Ctx131Malignant Pleural Mesothelioma, Pancreatic Adenocarcinoma, Cervical Carcinoma, Clear Cell Renal Cell Carcinoma, Esophageal CarcinomaPhase ICompletedA Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid TumorsMar 21, 2023―
Ctx001Hemoglobinopathies, Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hematological DiseasesPhase IIIActive Not RecruitingEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)Apr 07, 2022―
Ctx001Hemoglobinopathies, Beta-Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, ThalassemiaPhase IIIActive Not RecruitingEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)Apr 07, 2022―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Crispr Therapeutics (DE:1CG) have in its pipeline
Crispr Therapeutics AG DE:1CG is currently developing the following drugs: Ctx460, Ctx112, Ctx340, Ctx310, Ctx131, Ctx001, Ctx130, Ctx120, Ctx110. These drug candidates are in various stages of clinical development as the company works toward FDA approval.